Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus nab-paclitaxel/gemcitabine perioperative therapy in high-risk resectable/borderline resectable pancreatic cancer
ChiCTR2500114031Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic adenocarcinoma (PDAC) comparing AG regimen + nimotuzumab with Control: AG regimen + placebo (2 arms). Primary endpoint: Disease-free survival. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500114031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114031.